Alnylam Pharmaceuticals to Present Path to “Alnylam 2020” at R&D Day

- Ten Major Clinical Data Readouts Expected in 2016 –

- By End 2017, Expect Five or More Ongoing Phase 3 Trials and First Phase 3 Readout –

CAMBRIDGE, Mass.--()--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today at a presentation in New York City will discuss pipeline progress across its three strategic therapeutic areas (STArs) including: Genetic Medicines, Cardio-Metabolic Disease, and Hepatic Infectious Disease. The Company’s management will profile their mid-to-late stage RNAi therapeutic programs, specifically discussing the unmet medical need, clinical development plans and market potential for several innovative investigational medicines. In January 2016, the Company expects to provide additional specific 2016 guidance on pipeline programs in its three STArs.

Alnylam CEO John Maraganore, along with other members of the company’s leadership team, will provide a detailed review of key clinical development programs including the ATTR portfolio, fitusiran (ALN-AT3), ALN-CC5, ALN-AS1, and ALN-PCSsc. The Company will further underscore how it intends to deliver on its 2020 goals by:

  • Leveraging a strong cash position and strategic alliances;
  • Focusing on a reproducible and modular platform for drug discovery and development;
  • Generating competitive and differentiated therapeutic profiles; and
  • Tapping the large number of product opportunities focused on liver-expressed disease genes.

“With human proof-of-concept currently demonstrated in six programs and eight programs in total expected to be in clinical development by year-end 2015, we believe we are well on our way to achieve our Alnylam 2020 goals, where – by the end of 2020 – we expect to achieve a company profile with three marketed products, as well as ten clinical programs, including four in late stages of development, across our three STArs,” said John Maraganore, Ph.D., Chief Executive Officer of Alnylam. “With the financial resources to drive our pipeline forward, a reproducible and modular platform, demonstrated potent and durable knockdown of target proteins, and competitive and differentiated target profiles, we believe we have the key components in place to make a meaningful difference in the lives of patients and to maximize value for shareholders.”

At the event, the Company will also provide additional guidance on notable advances it anticipates over the next two years, including:

  • Ten major clinical data readouts expected in 2016; and,
  • Five or more Phase 3 trials ongoing and the first Phase 3 readout expected by the end of 2017.

Genetic Medicines STAr
Alnylam is advancing a broad pipeline of genetically validated liver disease targets for rare orphan diseases, with high unmet patient needs. This includes patisiran and revusiran, investigational RNAi therapeutics for the treatment of transthyretin-mediated amyloidosis (ATTR amyloidosis), now in Phase 3 clinical trials with the Company's APOLLO and ENDEAVOUR studies, respectively. APOLLO remains on track to complete enrollment in the next 2-3 months, which is expected to enable a New Drug Application (NDA) submission in 2017, while ENDEAVOUR continues enrollment. The Company will also discuss ALN-TTRsc02, which is expected to be filed as a Clinical Trial Application (CTA) in early 2016 and to enter Phase 3 in 2017.

In addition, the Company is advancing fitusiran (ALN-AT3), an investigational RNAi therapeutic in development for the treatment of hemophilia and rare bleeding disorders, where positive Phase 1 data including monthly dosing results were recently reported. The Company will discuss the potential commercial opportunity for fitusiran and will detail plans to advance to pivotal studies in mid-2016.

The clinical plan for ALN-CC5, being investigated for the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) and complement-mediated diseases, will also be covered. Recent positive Phase 1 data were reported, including robust and dose-dependent knockdown of serum C5 with very low levels of residual C5, in addition to effects on multiple measures of complement activity and a durability profile supportive of a monthly, or possibly quarterly, subcutaneous dose regimen. Enrollment in Part C in PNH patients is expected to start before year-end, with initial data planned to read out in mid-2016, ahead of an anticipated 2017 Phase 3 start.

Amongst other programs, the Company will provide an update on ALN-AS1, an investigational RNAi therapeutic in development for the treatment of acute hepatic porphyrias in which initial recently reported Phase 1 clinical data demonstrated rapid and durable single-dose activity. ALN-AS1 could address a major unmet need in an ultra-rare orphan disease, with potential to make a difference in patients afflicted with this condition.

Across its Genetic Medicines STAr, Alnylam plans to commercialize its products through direct marketing and sales in the U.S. and EU, while leveraging its landmark partnership with Genzyme, a Sanofi company, for commercialization in those countries of North America, Europe, and the rest-of-world where Genzyme has the right to access Alnylam’s current and future Genetic Medicines pipeline.

Cardio-Metabolic Disease STAr
In addition, Alnylam is advancing its pipeline of RNAi therapeutics toward genetically validated, liver-expressed disease targets for unmet needs in dyslipidemias, diabetes, NASH, and hypertension, amongst other diseases. The validated profile of ESC-GalNAc conjugates with a once-quarterly and possibly bi-annual, low-volume, subcutaneous dose regimen and a wide therapeutic index supports advancement of new investigational medicines in this disease area.

Alnylam is advancing ALN-PCSsc, an investigational RNAi therapeutic targeting PCSK9 for the treatment of hypercholesterolemia, in collaboration with The Medicines Company. Phase 1 clinical data with ALN-PCSsc was recently reported demonstrating PCSK9 knockdown and LDL-cholesterol lowering supportive of a highly differentiated target product profile with a potential for a bi-annual subcutaneous dose regimen. ORION-1, a Phase 2 clinical study in 480 patients with elevated LDL-C, is being conducted by The Medicines Company and expects to start by the end of this year.

Alnylam intends to seek strategic partnership opportunities for programs in its Cardio-Metabolic Disease STAr, while retaining significant product commercialization rights in the U.S. and EU.

Hepatic Infectious Disease
Finally, Alnylam is advancing a pipeline of RNAi therapeutics that address major global health challenges, including hepatitis B virus (HBV) and hepatitis D virus (HDV) infections, amongst other hepatic infectious disease opportunities.

ALN-HBV is an ESC-GalNAc-siRNA targeting the HBV genome and the company now plans to file a CTA for this program in early 2016, representing potentially a 3-4 month shift from earlier guidance. Alnylam is also advancing additional investigational programs including for the treatment of HDV infection and chronic liver infections.

The Company intends to seek strategic partnership opportunities for programs in its Hepatic Infectious Disease STAr, while retaining significant product commercialization rights in the U.S. and EU.

Alnylam will webcast its R&D Day live on the Investors section of the company's website, www.alnylam.com. The event will be held today from 8:00 a.m. to 11:30 a.m. ET at the Sofitel New York in New York City. An audio replay of the event will be available on the Alnylam website approximately 90 minutes after the event.

Genzyme Alliance
In January 2014, Alnylam and Genzyme, a Sanofi company, formed an alliance to accelerate and expand the development and commercialization of RNAi therapeutics across the world. The alliance is structured as a multi-product geographic alliance in the field of rare diseases. Alnylam retains product rights in North America and Western Europe, while Genzyme obtained the right to access certain programs in Alnylam's current and future Genetic Medicines pipeline in the rest of the world (ROW) through the end of 2019, together with certain broader co-development/co-commercialization rights and global rights for certain products. In the case of patisiran, Alnylam will advance the product in North America and Western Europe, while Genzyme will advance the product in the ROW. In the case of revusiran, Alnylam and Genzyme will co-develop/co-commercialize the product in North America and Western Europe, while Genzyme will advance the product in the ROW. In the case of fitusiran, Genzyme has elected to opt into the program for its rest-of-world rights, while retaining their further opt-in right to co-develop and co-promote fitusiran with Alnylam in North America and Western Europe, subject to certain restrictions.

About GalNAc Conjugates and Enhanced Stabilization Chemistry (ESC)-GalNAc Conjugates
GalNAc-siRNA conjugates are a proprietary Alnylam delivery platform and are designed to achieve targeted delivery of RNAi therapeutics to hepatocytes through uptake by the asialoglycoprotein receptor. Alnylam's Enhanced Stabilization Chemistry (ESC)-GalNAc-conjugate technology enables subcutaneous dosing with increased potency and durability, and a wide therapeutic index. This delivery platform is being employed in nearly all of Alnylam's pipeline programs, including programs in clinical development.

About RNAi
RNAi (RNA interference) is a revolution in biology, representing a breakthrough in understanding how genes are turned on and off in cells, and a completely new approach to drug discovery and development. Its discovery has been heralded as "a major scientific breakthrough that happens once every decade or so," and represents one of the most promising and rapidly advancing frontiers in biology and drug discovery today which was awarded the 2006 Nobel Prize for Physiology or Medicine. RNAi is a natural process of gene silencing that occurs in organisms ranging from plants to mammals. By harnessing the natural biological process of RNAi occurring in our cells, the creation of a major new class of medicines, known as RNAi therapeutics, is on the horizon. Small interfering RNA (siRNA), the molecules that mediate RNAi and comprise Alnylam's RNAi therapeutic platform, target the cause of diseases by potently silencing specific mRNAs, thereby preventing disease-causing proteins from being made. RNAi therapeutics have the potential to treat disease and help patients in a fundamentally new way.

About Alnylam Pharmaceuticals
Alnylam is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is leading the translation of RNAi as a new class of innovative medicines. Alnylam's pipeline of investigational RNAi therapeutics is focused in 3 Strategic Therapeutic Areas (STArs): Genetic Medicines, with a broad pipeline of RNAi therapeutics for the treatment of rare diseases; Cardio-Metabolic Disease, with a pipeline of RNAi therapeutics toward genetically validated, liver-expressed disease targets for unmet needs in cardiovascular and metabolic diseases; and Hepatic Infectious Disease, with a pipeline of RNAi therapeutics that address the major global health challenges of hepatic infectious diseases. In early 2015, Alnylam launched its "Alnylam 2020" guidance for the advancement and commercialization of RNAi therapeutics as a whole new class of innovative medicines. Specifically, by the end of 2020, Alnylam expects to achieve a company profile with 3 marketed products, 10 RNAi therapeutic clinical programs - including 4 in late stages of development - across its 3 STArs. The company's demonstrated commitment to RNAi therapeutics has enabled it to form major alliances with leading companies including Merck, Medtronic, Novartis, Biogen, Roche, Takeda, Kyowa Hakko Kirin, Cubist, GlaxoSmithKline, Ascletis, Monsanto, The Medicines Company, and Genzyme, a Sanofi company. In addition, Alnylam holds an equity position in Regulus Therapeutics Inc., a company focused on discovery, development, and commercialization of microRNA therapeutics. Alnylam scientists and collaborators have published their research on RNAi therapeutics in over 200 peer-reviewed papers, including many in the world's top scientific journals such as Nature, Nature Medicine, Nature Biotechnology, Cell, New England Journal of Medicine, and The Lancet. Founded in 2002, Alnylam maintains headquarters in Cambridge, Massachusetts. For more information about Alnylam's pipeline of investigational RNAi therapeutics, please visit www.alnylam.com.

Alnylam Forward Looking Statements
Various statements in this release concerning Alnylam's future expectations, plans and prospects, including without limitation, Alnylam's views with respect to the potential for RNAi therapeutics, including its ATTR portfolio, fitusiran (ALN-AT3), ALN-CC5, ALN-AS1, ALN-PCSsc, and ALN-HBV, its plans and expected timing regarding regulatory filings, including for patisiran, ALN-TTRsc02 and ALN-HBV, the expected timing for the initiation of additional clinical trials for its candidates, including the expected timing for the initiation of Phase 3 trials for ALN-TTRsc02 and fitusiran, plans for reporting data from its clinical trials, including ten major clinical data readouts expected in 2016, and its plans for the commercialization of RNAi therapeutics, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, Alnylam's ability to discover and develop novel drug candidates and delivery approaches, successfully demonstrate the efficacy and safety of its drug candidates, the pre-clinical and clinical results for its product candidates, which may not be replicated or continue to occur in other subjects or in additional studies or otherwise support further development of product candidates, actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials, obtaining, maintaining and protecting intellectual property, Alnylam's ability to enforce its patents against infringers and defend its patent portfolio against challenges from third parties, obtaining regulatory approval for products, competition from others using technology similar to Alnylam's and others developing products for similar uses, Alnylam's ability to manage operating expenses, Alnylam's ability to obtain additional funding to support its business activities and establish and maintain strategic business alliances and new business initiatives, Alnylam's dependence on third parties for development, manufacture, marketing, sales and distribution of products, the outcome of litigation, and unexpected expenditures, as well as those risks more fully discussed in the "Risk Factors" filed with Alnylam's most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) and in other filings that Alnylam makes with the SEC. In addition, any forward-looking statements represent Alnylam's views only as of today and should not be relied upon as representing its views as of any subsequent date. Alnylam explicitly disclaims any obligation to update any forward-looking statements.

Contacts

Alnylam Pharmaceuticals, Inc.
Christine Regan Lindenboom, 617-682-4340
(Investors and Media)
or
Josh Brodsky, 617-551-8276
(Investors)

Contacts

Alnylam Pharmaceuticals, Inc.
Christine Regan Lindenboom, 617-682-4340
(Investors and Media)
or
Josh Brodsky, 617-551-8276
(Investors)